GAMMA Investing LLC Has $91,000 Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

GAMMA Investing LLC increased its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 118.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,018 shares of the medical equipment provider’s stock after purchasing an additional 551 shares during the period. GAMMA Investing LLC’s holdings in Lantheus were worth $91,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Wilmington Savings Fund Society FSB acquired a new position in shares of Lantheus in the 3rd quarter worth approximately $25,000. Signaturefd LLC raised its stake in Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 92 shares in the last quarter. UMB Bank n.a. lifted its holdings in shares of Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after acquiring an additional 126 shares during the period. Kathleen S. Wright Associates Inc. acquired a new stake in shares of Lantheus in the 3rd quarter valued at $51,000. Finally, Nkcfo LLC bought a new stake in shares of Lantheus in the 2nd quarter worth about $47,000. Institutional investors own 99.06% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on LNTH. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Truist Financial reiterated a “buy” rating and issued a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. JMP Securities reduced their target price on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a report on Thursday, November 7th. Finally, The Goldman Sachs Group began coverage on Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target for the company. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $131.86.

Lantheus Price Performance

LNTH stock opened at $95.88 on Friday. The company has a 50 day moving average price of $90.39 and a 200 day moving average price of $99.54. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The stock has a market capitalization of $6.67 billion, a PE ratio of 15.95 and a beta of 0.46.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.